Harmony Biosciences Holdings, Inc. — Cyborg Score 8/10
Strong
Pharmaceuticals - Rare/Specialty Diseases
Strategic Profile
WAKIX generated $868 million in 2025 preliminary revenue with 2026 guidance of $1.0-$1.04 billion, demonstrating strong commercial execution. The company is expanding pitolisant across multiple neurological indications including Prader-Willi Syndrome in Phase 3 trials and Myotonic Dystrophy in Phase 2, while evaluating broader applications for H3 receptor-mediated disorders.
Cyborg Score Rationale
Strong WAKIX revenue growth trajectory with blockbuster status potential and pipeline expansion extending into the 2040s. Expanding addressable markets with a diversified pipeline and strong commercial execution position the company for sustained revenue growth and continued R&D investment.
Top Insights
WAKIX achieving blockbuster status with $868M in 2025 revenue and $1.0-1.04B guidance for 2026 demonstrates exceptional market penetration
FDA approval of WAKIX for pediatric cataplexy treatment in February 2026 expands addressable market
Diversified pipeline with Pitolisant variants in development (GR, HD formulations), Phase 3 trials for Fragile X and 22q Deletion Syndrome, plus multiple novel mechanism compounds targeting rare epilepsies and neurological disorders
Evolving payer and regulatory landscapes present risks to pricing power and long-term earnings visibility
Named Competitors
Narcolepsy Treatments — Alternative narcolepsy medications